D NET logo

The IDF Diabetes Network for Health Professionals - D-NET - is the only online platform with an international reach for health professionals engaged in diabetes care. This innovative and exciting online platform offers the opportunity to connect with diabetes professionals worldwide and share, learn and discuss the latest developments in diabetes care and education.

As a member of D-NET you are part of a dynamic community of diabetes health professionals interested in improving their practice and learning from other professionals from around the globe. The network provides a forum for health professionals to communicate and grow professionally.

Join D-NET now!

school web image

415 million people globally have diabetes, if nothing is done, it is estimated that this number will rise to 642 million in 2040.

1 in 5 healthcare professionals do not receive any postgraduate training in diabetes. Less than 1 in 2 people with diabetes and 1 in 4 family members of people with diabetes have access to diabetes education programmes. Education of people with diabetes is a critically important, fundamental and an integral component of diabetes care that should be available and accessible to everyone.

IDF recognises the value of providing continued professional education for health professionals and resources for people with diabetes and caregiver in a sustainable and convenient manner.

Building on its long track record of developing evidence-based educational resources for both people living with diabetes and health professionals, IDF has developed the IDF School of Diabetes to deliver high standard, evidence-based diabetes education for health professionals, people with diabetes and caregivers worldwide.

The IDF School of Diabetes features three tailor-made certified courses:

  • IDF Certified Course for Diabetes Educators: intended to enhance core skills and competencies of health professionals to effectively educate people with diabetes, to promote healthy lifestyles and effective self-management for optimal diabetes control.
  • IDF Certified Course for Primary Care Physicians and General Practitioners: intended to impart up-to-date evidence-based knowledge and to enhance core competencies of primary care physicians and general practitioners to address the prevention, early detections and management of diabetes.
  • IDF Certified Course for Specialists: intended to provide diabetelogists, endocrinologists, consultants and equivalent specialists with the latest advances in the treatment and management of diabetes.

Register now to access the courses and take the free trial modules!

Download a detailed overview of the certified courses.

The following scientific posters related to the content of the IDF Diabetes Atlas have been published.


One scientific poster about IDF Atlas data was presented at the 77th American Diabetes Association Scientific Sessions in New Orleans, 2016:


Two scientific posters about IDF Atlas data were presented at the 76th American Diabetes Association Scientific Sessions in New Orleans, 2016:


Three scientific posters about IDF Atlas data were presented at the 75th American Diabetes Association Scientific Sessions in Boston, 2015:

One scientific poster was presented at the European Congress of Epidemiology in Maastricht, 2015:

One scientific poster was presented at the Epidemiology Symposium 'Methods in Epidemiology' 2015 in Leuven, 2015: 

One scientific poster was presented at 14th Symposium of the International Diabetes Epidemiology Group, in Vancouver, Canada, 2015: 

Diabetes is a global issue. Type 2 Diabetes (T2DM) is the most common form of diabetes. Around 90% of people with diabetes have type 2 diabetes. From the onset of the disease until the symptoms developed, many people with undiagnosed diabetes already have complications such as chronic kidney disease, heart failure, retinopathy and neuropathy. Early detection, diagnosis, and cost-effective treatments can save lives and prevent or significantly delay devastating diabetes-related complications.

In many cases, type 2 diabetes can be prevented by adopting a healthy lifestyle. Much can be done to improve the quality of life, increase physical activity, and reduce morbidity and mortality in people living with diabetes. The new IDF Clinical Practice Recommendations for managing Type 2 Diabetes in Primary Care guidelines seek to summarise current evidence around optimal management of people with type 2 diabetes. It is intended to be a decision support tool for general practitioners, hospital based clinicians and other primary health care clinicians working in diabetes.

The development of these guidelines has been a highly consultative process, evidence- based, incorporating recent advances in diabetes management and emerging treatment opportunities.

A guideline is only valuable and useful when it is implemented in the field for the day-to-day clinical practice. Therefore, IDF recommends to all clinicians from all over the world to use these recommendations for an optimal management of type 2 diabetes in their settings.

Diabetes is a global epidemic that affects everyone. The numbers are staggering: 415 million people were living with diabetes in 2015, another 318 million people were at high risk of developing type 2 diabetes, and diabetes was responsible for 5 million deaths. Worryingly, the epidemic shows no signs of relenting, with the number of people living with diabetes expected to reach 642 million by 2040. Diabetes has an enormous human, social and economic impact, with one in eight health dollars currently spent on treating the disease and its associated complications.

Despite these alarming statistics, cost-effective solutions exist to reduce the global burden that diabetes currently poses. Much can be done to prevent the onset of type
2 diabetes, as outlined in the IDF Cost-effective solutions for the prevention of type 2 diabetes report, which provides an overview of the latest evidence on the different programmes available to tackle the rise of the most prevalent form of diabetes. The wide range of options presented and their cost-saving implications give cause for optimism that the current situation can be reversed.

Intensive lifestyle modification, involving the adoption of healthy diets and increased physical activity, remains the cornerstone for the prevention of type 2 diabetes. This report discusses in detail the components of a successful lifestyle modification programme, the benefits of using certain medications for primary prevention, and provides an analysis of different public health measures to promote healthier behaviours.

The intention of this report is to provide policy makers and diabetes advocates with an accessible and comprehensive summary of the current data on the clinical effects of primary prevention programmes, the costs associated with their delivery, and the resulting benefits for our societies. Evidence on actionable solutions is also included to inform policy development.

Successful prevention of type 2 diabetes will only be achievable through concrete and effective action at the community level. We hope that the practical solutions outlined in this report will help those active on the ground to change the diabetes landscape to achieve a healthier future for all.

Driving early action in type 2 diabetes

In December 2016, diabetes experts representing 38 countries convened in Berlin to launch The Berlin Declaration, a global call to action urging policy makers to reduce the growing burden of type 2 diabetes.

Their recommendations focus on four pillars of ‘Early Action’ in type 2 diabetes: preventing diabetes, diagnosing it early, controlling it early and ensuring early access to the right personalised interventions. If adopted by national health systems, the recommendations are expected to help countries meet voluntary global diabetes targets set by the United Nations1 and the World Health Organization.2 If policy makers fail to take action, health system costs are expected to increase by $129 billion by 2040.

Experts issued their call for early action at the Global Diabetes Policy Forum on Early Action in Type 2 Diabetes in Berlin on 13-14 December 2016. The meeting was organised and funded by AstraZeneca in collaboration with the International Diabetes Federation (IDF), Primary Care Diabetes Europe (PCDE), and the World Heart Federation (WHF), and supported by German Diabetes Aid (GDA). The Forum took forward the work begun under the banner of ‘Early Action in Diabetes’ at the first Global Diabetes Policy Summit, held in Barcelona, Spain, in November 2015. Participants in the Berlin Forum included leading clinical experts in diabetes as well as patient group representatives, policy makers and political leaders.

The Berlin Declaration is the output of the work of 23 diabetes experts from 11 countries who volunteered to participate in four international working groups established at the 2015 Summit in Barcelona. The groups were tasked to review best practice in policy making in diabetes prevention, early detection, early control and early access to the right interventions. Each group convened at least twice during 2016 in order to contribute to The Berlin Declaration.

“I’m delighted that the International Diabetes Federation is helping to champion this important initiative,” said IDF president Dr Shaukat Sadikot. “What sets ‘Early Action’ apart from other campaigns is its focus on real action on the ground, aimed at producing concrete benefits for people with diabetes in countries at all levels of income. Every six seconds, someone in the world dies from diabetes. This sobering fact makes it absolutely critical that policy makers take action now, and that a broad range of stakeholders come together to encourage and support needed policy reform.”

Download the Berlin Declaration

© 2017 International Diabetes Federation Disclaimer